Sulphonylurea efficacy and end‐organ outcomes in the management of <scp>HNF4A</scp> ‐ <scp>MODY</scp>
Individuals with an HNF4A mutation and normal BMI are likely to respond to sulphonylurea therapy. Avoidance of weight gain is associated with ongoing responsiveness to monotherapy. Adjunct therapies including GLP1RA and SGLT2i may play a role in further glycaemic management in addition to renal protective and cardioprotective effects.
Authors
- Sarah J. Bacon (ORCID: https://orcid.org/0009-0000-1594-1741)
- Kevin Colclough (ORCID: https://orcid.org/0000-0003-0566-4853)
- Stephen Ludgate (ORCID: https://orcid.org/0000-0002-9597-9471)
- Begoña Sánchez Lechuga (ORCID: https://orcid.org/0000-0002-4352-9655)
- Mairéad T. Crowley (ORCID: https://orcid.org/0000-0002-7735-9711)
- Marie Burke
- Eirena L. Goulden (ORCID: https://orcid.org/0000-0003-1048-3176)
- Nicholas Ng (ORCID: https://orcid.org/0000-0003-0076-672X)
- Maria M. Byrne (ORCID: https://orcid.org/0000-0002-9394-8698)
Institutions
- University College Dublin (IE)
- University of Exeter (GB)
- Mater Misericordiae University Hospital (IE)
Publication Details
- Journal
- Diabetic Medicine
- Published
- 2025-09-15
- DOI
- https://doi.org/10.1111/dme.70139
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00